| 摘要: |
| ［摘要］ 目的 探讨恩替卡韦抗病毒治疗对HBV-DNA阳性的原发性肝癌（HCC）患者术后转归的影响。方法 将60例HBV-DNA阳性HCC根治术后患者随机分为观察组35例和对照组25例，两组均常规给予抗炎及保肝药物治疗，另观察组于根治术后1～2周开始服用恩替卡韦分散片（0.5 mg/d）抗乙肝病毒治疗，疗程均>48周，对照组未行抗病毒治疗。比较两组患者治疗前后肝功能、HBV-DNA定量、AFP及无瘤生存率等情况。结果 (1)观察组3个月、6个月HBV-DNA载量、AFP水平下降较对照组显著（P<0.01）。（2）观察组1个、6个月ALT、AST、ALP、GGT水平均有所下降，而对照组1个月未见明显变化，6个月反而有所升高，两组比较差异有统计学意义（P<0.01）。（3）随访3年，死亡19例，其中观察组6例，对照组13例，两组无瘤生存率比较差异有统计学意义（P<0.01）。结论 恩替卡韦抗病毒治疗能有效降低病毒载量，改善肝癌根治术后肝脏功能，降低复发率，延长生存时间，具有较好的临床效果。 |
| 关键词: 肝癌 乙型肝炎 抗病毒治疗 根治术 |
| DOI：10.3969/j.issn.1674-3806.2016.02.14 |
| 分类号:R 735.7 |
| 基金项目: |
|
| Clinical study of entecavir on treating hepatitis B related hepatic carcinoma after radical operation |
|
LIN Qing, LI Min-jie, LI Hai-qiang, et al.
|
|
Department of Liver and Stomach, Hezhou Hospital of Traditional Chinese Medicine, Guangxi 542809, China
|
| Abstract: |
| ［Abstract］ Objective To explore the effects of entecavir on the antiviral treatment for HBV-DNA positive primary hepatocellular carcinoma(HCC).Methods 60 patients with HBV-DNA positive HCC after radical operation were randomly divided into the observation group（n=35） and the control group（n=25）. Both of the two groups received the conventional anti-inflammatory therapy and liver-protecting treatment. Besides, entecavir was given to the observation group as an anti-HBV therapy 0.5 mg per day for more than 48 weeks 1 to 2 weeks after the radical operation. The liver function, HBV-DNA ration, AFP and disease-free survival rate of the patients were compared between the two groups.Results （1）HBV-DNA loads and AFP level declined in the observation group significantly than those did in the control group after 3 and 6 months′ treatment(P<0.01); （2）The levels of ALT, AST, ALP, GGT in the observation group declined after 1 and 6 month′s treatment. There were no significant changes of the levels of ALT, AST, ALP, GGT in the control groups after 1 month′s treatment. On the contrary, the levels of the above indicators increased after 6 months′ treatment in the control groups. There were significant differences on the levels of the indicators between the two groups(P<0.01); （3）Followed up for 3 years, 19 cases died, in which 13 cases were in the control group and 6 cases in the observation group, with a significantl difference in disease-free survival rate between the two groups(P<0.01).Conclusion Entecavir Antiviral treatment with entecavir can reduce the viral load, improve liver function after radical operation, reduce the recurrence rate and prolong the survival time. |
| Key words: Hepatic carcinoma Hepatitis B Antiviral treatment Radical operation |
